FORXIGA® (dapagliflozin)

FORXIGA® (dapagliflozin) is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

FORXIGA®(dapagliflozin) in secondary care

Start change earlier for your patients

Consider FORXIGA® (dapagliflozin) ahead of a GLP-1 for:

  • A numerically similar reduction in HbA1c to once-weekly exenatide, a GLP-1 (in an RCT)10
  • The secondary benefit of weight loss, proportional to patient BMI1,4
  • Simple dosing1

RCT randomised controlled trial.

What could FORXIGA® (dapagliflozin) do for your patients ahead of a GLP-1 and across the treatment pathway?

FORXIGA®  (dapagliflozin) can be used in combination with insulin, with data available up to 104 weeks32

Reduction in HbA1c from baseline at over 104 weeks (FORXIGA® + insulin vs placebo + insulin)
Reduction in HbA1c from baseline at over 104 weeks (FORXIGA® + insulin vs placebo + insulin)

Adapted from Wilding JP et al. 2014

At 24 weeks (primary endpoint), mean HbA1c was reduced by 0.96% with FORXIGA® (dapagliflozin) compared with 0.39% with placebo (p<0.001, mean difference 0.57% [CI 0.42%, 0.72%]).36

In a Phase 3 trial, FORXIGA® (dapagliflozin) showed:

  • A numerically similar reduction in HbA1c to once-weekly exenatide (a GLP-1)10
  • A 2% reduction in HbA1c at 28 weeks when given in combination with once-weekly exenatide (as a dual add on)10
  • No new, or unexpected, safety findings for Bydureon or Forxiga were noted during the DURATION-8 trial, consistent with the PI, over 52 weeks10

Reduction from baseline in HbA1c at week 28 with FORXIGA® (dapagliflozin), exenatide and FORXIGA® (dapagliflozin) + exenatide10

Reduction in HbA1c from baseline at week 28 with FORXIGA®, exenatide and FORXIGA® + exenatide
Reduction in HbA1c from baseline at week 28 with FORXIGA®, exenatide and FORXIGA® + exenatide

Adapted from Frías JP et al. 2016.

Statistical significance for the between-group difference was not tested.10
GLP-1, glucagon-like peptide 1; LS, least-squares; CI, confidence interval.